Construction and Validation of a Macrophage-Associated Risk Model for Predicting the Prognosis of Osteosarcoma

Table 4

Potential drugs for the treatment of osteosarcoma by cMap analysis.

cMap name	Mean	n	Enrichment		Specificity	Percent nonnull
Exisulind	−0.516	2	−0.874	0.03167	0.0287	100
Chenodeoxycholic acid	−0.549	4	−0.698	0.01751	0.1	75
Atractyloside	−0.445	5	−0.695	0.00581	0.0227	60
Clorsulon	−0.409	4	−0.687	0.02077	0.0567	50
Doxycycline	−0.391	5	−0.664	0.01007	0.0226	60
Paromomycin	−0.515	4	−0.654	0.03296	0	75
Naltrexone	−0.352	5	−0.643	0.01448	0.0562	60
Chlormezanone	−0.426	4	−0.641	0.03975	0.0276	75
Indometacin	0.165	8	0.508	0.01946	0.0156	50
Flufenamic acid	0.305	6	0.527	0.04479	0.0511	50
Prilocaine	0.31	6	0.531	0.04177	0.0081	50
Orphenadrine	0.455	6	0.561	0.02674	0.0461	66
Hydralazine	0.259	6	0.607	0.0114	0	50